199 related articles for article (PubMed ID: 35814516)
1. Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis.
Kovalic AJ
J Clin Exp Hepatol; 2022; 12(4):1057-1068. PubMed ID: 35814516
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Singh S; Khera R; Allen AM; Murad MH; Loomba R
Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Marey MM; Belal M; Awad AA; Rabea EM; Hassan MA; Abbas AW; Nashwan AJ
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102357. PubMed ID: 38688423
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Yi H; Sun W; Yu H; Tao W; Yu X; Jia D; Liu Y; Pandol SJ; Li L
Drugs; 2024 Apr; 84(4):425-439. PubMed ID: 38478331
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
Majzoub AM; Nayfeh T; Barnard A; Munaganuru N; Dave S; Singh S; Murad MH; Loomba R
Aliment Pharmacol Ther; 2021 Oct; 54(7):880-889. PubMed ID: 34435378
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
9. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.
Pennisi G; Celsa C; Enea M; Vaccaro M; Di Marco V; Ciccioli C; Infantino G; La Mantia C; Parisi S; Vernuccio F; Craxì A; Cammà C; Petta S
Nutr Metab Cardiovasc Dis; 2022 Oct; 32(10):2279-2288. PubMed ID: 35970684
[TBL] [Abstract][Full Text] [Related]
10. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
[TBL] [Abstract][Full Text] [Related]
11. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.
Sawangjit R; Chongmelaxme B; Phisalprapa P; Saokaew S; Thakkinstian A; Kowdley KV; Chaiyakunapruk N
Medicine (Baltimore); 2016 Aug; 95(32):e4529. PubMed ID: 27512874
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
14. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
[TBL] [Abstract][Full Text] [Related]
15. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
Heath L; Aveyard P; Tomlinson JW; Cobbold JF; Koutoukidis DA
Hepatol Commun; 2022 Oct; 6(10):2623-2633. PubMed ID: 35903833
[TBL] [Abstract][Full Text] [Related]
16. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.
Kovalic AJ; Gozar M; Da BL; Bernstein D; Satapathy SK
Eur J Gastroenterol Hepatol; 2023 Jan; 35(1):102-111. PubMed ID: 36468574
[TBL] [Abstract][Full Text] [Related]
18. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
[TBL] [Abstract][Full Text] [Related]
20. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
